What are ADC's

Our services

ADC Review
is made possible by:


Study Title
Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma (NCT00354107)

Trial Description
This phase I/II trial is studying the side effects and best dose of SGN-30 when given together with ifosfamide, carboplatin, and etoposide and to see how well they work in treating young patients with recurrent anaplastic large cell lymphoma. Drugs used in chemotherapy, such as ifosfamide, carboplatin, and etoposide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.

Monoclonal antibodies, including antibody-drug conjugates such as SGN-30, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them.

This trial is sponsored by National Cancer Institute (NCI). [1]

Study Data

  • Condition: 
    • Anaplastic Large Cell Lymphoma
    • Recurrent Childhood Anaplastic Large Cell Lymphoma
  • Interventions:
  • Phase: I & II
  • Enrollment: 5
  • Start: January 2007
  • Completion: January 2010
  • Last verified: October 2011

Study Schematic

Screen Shot 2016-07-18 at 3.40.07 PM

Click here to Return to Drug map

Last Editorial review: July 17, 2016
Information based on (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...

Skip to toolbar